Fosså S D, Thorud E, Pettersen E O, Shoaib M C, Scott-Knudsen O, Ous S
Pathol Res Pract. 1986 Jun;181(3):291-5. doi: 10.1016/S0344-0338(86)80105-4.
The cell kinetic fractions (G0/G1; S; G2 + M) were evaluated by DNA flow cytometry (DNA FCM) in 102 biopsies from bladder carcinoma, previously untreated by cytotoxic therapy, and in 25 biopsies taken at least 3 months after prior treatment (chemotherapy, radiotherapy, surgery). Non-diploid DNA-stemlines were most often found in tumours of a high T category and of a high histopathological grade. Also the number of tumours with a fraction of cells in S-phase above 10% correlated with the clinical stage and histological grade. When the cytotoxic treatment preceded the actual biopsy by 3 months or more the distribution of stemline ploidies in the recurrent or residual tumours were similar to that seen in previously untreated patients. Furthermore, 4 of 5 individual muscle infiltrating bladder tumours treated with surgery, radiotherapy or systemic chemotherapy had the same stemline ploidy before and after treatment. The analysis of ploidy and cell kinetic parameters obtained from DNA FCM offers a possibility to evaluate the prognosis and the therapy effects in human bladder carcinoma.
通过DNA流式细胞术（DNA FCM）对102例未经细胞毒性治疗的膀胱癌活检样本以及25例在先前治疗（化疗、放疗、手术）后至少3个月采集的活检样本进行细胞动力学组分（G0/G1；S；G2 + M）评估。非二倍体DNA干系最常见于高T类别和高组织病理学分级的肿瘤中。此外，处于S期的细胞比例高于10%的肿瘤数量与临床分期和组织学分级相关。当细胞毒性治疗在实际活检前3个月或更长时间进行时，复发或残留肿瘤中干系倍体的分布与未经治疗患者中所见相似。此外，5例接受手术、放疗或全身化疗的浸润性膀胱肿瘤患者中有4例在治疗前后具有相同的干系倍体。从DNA FCM获得的倍体和细胞动力学参数分析为评估人类膀胱癌的预后和治疗效果提供了一种可能。
